Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.
Morepen Laboratories' Board has proposed a final dividend of ₹ 0.20 per equity share for the financial year, subject to shareholder approval at the upcoming AGM. The dividend record date is September 19.
Morepen Labs invested ₹20 Cr in its wholly-owned pharma subsidiary, Morepen RX Ltd, via a rights issue. This capital infusion strengthens MRX's base and supports its branded Rx products business. MRX reported a FY26 turnover of ₹54.49 Cr.